It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for treating all myelodysplastic syndromes (MDS) subtypes.
Azacitidine
Brand name:
5-azacytidine, Vidaza
Related Clinical Trials
Clinical Trial | Status | Age Group |
---|---|---|
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | Recruiting | 18 years and older |
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | 18 years and older |
AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.